Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation

Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work better for STK11 or KEAP1 mutated (SKmut) aNSCLC pa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Nie, Wei, Gan, Lu, Wang, Xin, Gu, Kai, Qian, Fang-Fei, Hu, Min-Juan, Zhang, Ding, Chen, Shi-Qing, Lu, Jun, Cao, Shu-Hui, Li, Jing-Wen, Wang, Yue, Zhang, Bo, Wang, Shu-Yuan, Li, Chang-Hui, Yang, Ping, Xu, Mi–Die, Zhang, Xue-Yan, Zhong, Hua, Han, Bao-Hui
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2021
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7833760/
https://ncbi.nlm.nih.gov/pubmed/33537171
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1865670
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge